Yosemite
VC Fund
San Francisco, United States
Yosemite is a venture capital firm that seeks to invest in early-stage companies.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries Yosemite invests in
Stages Yosemite invests in
Countries Yosemite invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Reed Jobs
|
|||
Investment Focus
Industry
- Health Care 9 (47%)
- Biotechnology 7 (37%)
- Medical 6 (32%)
- Artificial Intelligence 4 (21%)
- Software 2 (11%)
Stage
- Series A 6 (32%)
- Seed 5 (26%)
- Series B 3 (16%)
- Series C 2 (11%)
- Funding Round 2 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Reed Jobs
Founder
|
Founder | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Chai Discovery
|
Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $400M / Series C / Jul 14, 2026 | |
HistoSonics
|
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | Jun 22, 2026 | |
Turquoise
|
Turquoise Health is a health tech company that simplifies administration to reduce the expense and complexity of healthcare. The company was founded in 2020 and is a fully remote company headquartered in San Diego, California, United States. | $40M / Series C / Mar 17, 2026 | |
Ten63 Therapeutics
|
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | |
Proxima
|
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | |
|
Chai Discovery
|
Chai Discovery creates Chai-1, a multi-modal foundation model designed for predicting molecular structures relevant to drug discovery. The model facilitates the unified prediction of proteins, small molecules, and nucleic acids, and is available for free for commercial applications. By enabling accurate predictions without the need for multiplesequence alignments, Chai-1 advances the capabilities of molecular modeling in the life sciences. | $130M / Series B / Dec 15, 2025 | |
Quarry Thera
|
Quarry Thera is a biotech company distinguished by its innovative therapeutic pipeline and an unprecedented platform that enables the development of cutting-edge treatments with the potential to address significant unmet medical needs. | $32M / Series A / Nov 26, 2025 | |
Solve Therapeutics
|
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics. The company was founded in 2021 and is headquartered in Belmont, California. | $120M / Series A / Nov 17, 2025 | |
Azalea Therapeutics
|
Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $65M / Series A / Nov 04, 2025 | |
|
Azalea Therapeutics
|
Azalea Therapeutics is a biotechnology company pioneering precision genome engineering directly inside the body, with a primary focus on developing cancer immunotherapies. Their innovative approach uses Envelope Delivery Vehicles (EDVs) to selectively locate and deliver genome editing tools to T cells within the patient, enabling the engineering ofthese cells in vivo rather than ex vivo (outside the body). This method aims to transform the patient’s own T cells into powerful cancer therapies safely and efficiently. | $17M / Seed / Nov 04, 2025 | |
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Yosemite invest in?
Yosemite invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yosemite?
Public channels for Yosemite include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Yosemite?
The team at Yosemite includes Reed Jobs (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
